Press
releases

Feb 15, 2024

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Read more
Feb 08, 2024

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update

Read more
Feb 06, 2024

Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

Read more
Feb 05, 2024

Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome

Read more
Jan 25, 2024

Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Read more
Jan 19, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
Jan 07, 2024

Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

Read more
Jan 04, 2024

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Read more
Jan 03, 2024

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome

Read more
Jan 02, 2024

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Read more
Sign up for Email Alerts
Email Alerts Sign-up